Mainstay medical announces publication of three-year clinical trial data from post-market clinical follow-up registry of reactiv8® in the united kingdom

Dublin--(business wire)--mainstay medical holdings plc today announced the publication of three-year clinical data from the post-market clinical follow-up (pmcf) study of 33 reactiv8 patients from five medical centres across the united kingdom. the three-year results, published in british journal of pain, demonstrated that a substantial portion of patients experienced statistically significant improvements in measures of pain (nrs), disability (odi) and quality of life (eq-5d-5l). the publicati.
UAL Ratings Summary
UAL Quant Ranking